[go: up one dir, main page]

ECSP13012997A - Antídotos anticoagulantes - Google Patents

Antídotos anticoagulantes

Info

Publication number
ECSP13012997A
ECSP13012997A ECSP13012997A ECSP13012997A EC SP13012997 A ECSP13012997 A EC SP13012997A EC SP13012997 A ECSP13012997 A EC SP13012997A EC SP13012997 A ECSP13012997 A EC SP13012997A
Authority
EC
Ecuador
Prior art keywords
antidotes
anticoagulant
anticoagulant antidotes
anticoagulants
relates
Prior art date
Application number
Other languages
English (en)
Inventor
Norbert Hauel
Sanjaya Singh
Ryn Joanne Van
Tobias Litzenburger
Keith Canada
Alisa Waterman
Robert Copenhaver
Christopher Ronald Sarko
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45876804&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13012997(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ECSP13012997A publication Critical patent/ECSP13012997A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a moléculas de anticuerpo contra anticoagulantes, en particular dabigatran, y a su uso como antídotos de dichos anticoagulantes.
ECSP13012997 2011-03-30 2013-10-25 Antídotos anticoagulantes ECSP13012997A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161469207P 2011-03-30 2011-03-30

Publications (1)

Publication Number Publication Date
ECSP13012997A true ECSP13012997A (es) 2013-12-31

Family

ID=45876804

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012997 ECSP13012997A (es) 2011-03-30 2013-10-25 Antídotos anticoagulantes

Country Status (23)

Country Link
US (2) US8821871B2 (es)
EP (1) EP2691156A1 (es)
JP (1) JP2014515740A (es)
KR (1) KR20140009437A (es)
CN (1) CN103476459A (es)
AP (1) AP2013007046A0 (es)
AR (1) AR085758A1 (es)
BR (1) BR112013025031A2 (es)
CA (1) CA2827787A1 (es)
CL (1) CL2013002551A1 (es)
CO (1) CO6771448A2 (es)
EA (1) EA201301090A1 (es)
EC (1) ECSP13012997A (es)
IL (1) IL227653A0 (es)
MA (1) MA34978B1 (es)
MX (1) MX2013011092A (es)
PE (1) PE20140964A1 (es)
PH (1) PH12013501924A1 (es)
SG (1) SG193552A1 (es)
TN (1) TN2013000388A1 (es)
TW (1) TW201302796A (es)
UY (1) UY33994A (es)
WO (1) WO2012130834A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE035281T2 (en) 2011-01-14 2018-05-02 Univ California Therapeutic antibodies against ror-1 protein and methods for use of same
PL2785700T3 (pl) 2011-11-29 2016-09-30 Środki odwracające działanie przeciwzakrzepowe
JP6824735B2 (ja) 2013-06-06 2021-02-03 ピエール、ファーブル、メディカマン 抗Ｃ１０ｏｒｆ５４抗体およびその使用方法
CN105492446B (zh) * 2013-07-30 2018-08-03 爱尔兰詹森科学公司 用于治疗病毒性感染的噻吩并[3,2-d]嘧啶衍生物
KR101523503B1 (ko) * 2013-09-17 2015-05-29 강원대학교산학협력단 아디포넥틴으로부터 유래한 펩타이드 및 이를 포함하는 조성물
JP2016539926A (ja) 2013-10-25 2016-12-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗凝血薬の解毒剤
EP2980218A1 (en) * 2014-07-30 2016-02-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamer thrombin complex for use as an antidote to direct acting thrombin inhibitors
EP3784281A4 (en) * 2018-04-27 2022-02-16 Seattle Children's Hospital d/b/a Seattle Children's Research Institute IN VIVO GENE THERAPY INVOLVING THE ADMINISTRATION OF A LENTIVIRAL GENE CONSTRUCTION

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
JP2919890B2 (ja) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ATE151113T1 (de) 1992-01-23 1997-04-15 Merck Patent Gmbh Fusionsproteine von monomeren und dimeren von antikörperfragmenten
DE4203965A1 (de) 1992-02-11 1993-08-12 Max Planck Gesellschaft Antidot fuer hirudin und synthetische thrombininhibitoren
ATE452207T1 (de) 1992-08-21 2010-01-15 Univ Bruxelles Immunoglobuline ohne leichte ketten
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
EP0703925B1 (en) 1993-06-03 1999-08-18 Therapeutic Antibodies Inc. Production of antibody fragments
AT404357B (de) 1995-06-13 1998-11-25 Immuno Ag Prothrombin-derivate
DE19605126A1 (de) 1996-02-12 1997-08-14 Basf Ag Thrombinmuteine als Antidot für Thrombininhibitoren
US6200955B1 (en) 1996-06-11 2001-03-13 Commonwealth Biotechnologies, Inc. Heparin binding peptides
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
US6323322B1 (en) 1997-04-30 2001-11-27 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
US6440417B1 (en) 1998-11-06 2002-08-27 Conjuchem, Inc. Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
EP2067488A1 (en) 2000-04-12 2009-06-10 Human Genome Sciences, Inc. Albumin fusion proteins
KR100927261B1 (ko) 2001-01-17 2009-11-18 트루비온 파마슈티칼스, 인코포레이티드 결합 도메인-면역글로불린 융합 단백질
US20040097547A1 (en) 2001-04-16 2004-05-20 Taveras Arthur G. 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
EP1456410A2 (en) 2001-12-11 2004-09-15 AlgoNomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
ES2263984T3 (es) 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
JP2006524036A (ja) 2002-11-08 2006-10-26 アブリンクス エン．ヴェー． 腫瘍壊死因子αを標的とする単一ドメイン抗体およびその使用
EP2221317A3 (en) 2003-06-30 2011-07-27 Domantis Limited PEGylated single domain antibodies (dAb)
EP3824902A1 (en) 2007-09-28 2021-05-26 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
ES2436076T3 (es) 2009-08-24 2013-12-26 Boehringer Ingelheim International Gmbh Intervenciones de urgencia de carbón vegetal activo con sobredosificación con etexilato de dabigatrán
TWI513466B (zh) * 2010-01-20 2015-12-21 Boehringer Ingelheim Int 抗凝血劑解毒劑

Also Published As

Publication number Publication date
PH12013501924A1 (en) 2017-10-25
TW201302796A (zh) 2013-01-16
US20140377265A1 (en) 2014-12-25
NZ613543A (en) 2015-07-31
UY33994A (es) 2012-09-28
WO2012130834A1 (en) 2012-10-04
AP2013007046A0 (en) 2013-08-31
MA34978B1 (fr) 2014-03-01
CA2827787A1 (en) 2012-10-04
JP2014515740A (ja) 2014-07-03
BR112013025031A2 (pt) 2017-08-01
CO6771448A2 (es) 2013-10-15
US8821871B2 (en) 2014-09-02
IL227653A0 (en) 2013-09-30
CL2013002551A1 (es) 2014-02-14
MX2013011092A (es) 2013-12-06
SG193552A1 (en) 2013-11-29
EA201301090A1 (ru) 2014-05-30
EP2691156A1 (en) 2014-02-05
US20120276123A1 (en) 2012-11-01
AR085758A1 (es) 2013-10-23
PE20140964A1 (es) 2014-08-17
TN2013000388A1 (en) 2015-01-20
KR20140009437A (ko) 2014-01-22
CN103476459A (zh) 2013-12-25

Similar Documents

Publication Publication Date Title
ECSP12012105A (es) Antídotos de Anticoagulantes
CY1121497T1 (el) Συριγγα
CY1121862T1 (el) Αντισωματα anti-phf-tau και χρησεις αυτων
ECSP13012997A (es) Antídotos anticoagulantes
CR20150329A (es) Inmunoglobulinas heterodiméricas
BR112014030278A2 (pt) anticorpo, e, composição.
MX382840B (es) Regiones de anticuerpo modificado y sus usos.
ECSP14027269A (es) Picolinamidas macrocíclicas como fungicidas
UY34680A (es) Anticuerpos humanos anti-cd27, métodos, y usos
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
EP2877490A4 (en) DIVIDED INTEINS, CONJUGATES THEREOF AND USES THEREOF
HRP20182098T1 (hr) Anti-angptl3 antitijela i njihove primjene
BR112014012137A2 (pt) anticorpos anti-fgfr2 e suas utilizações
IL231777A0 (en) Antibodies against tl1a and uses thereof
CL2015001266A1 (es) Anticuerpos de antihemaglutinina y métodos de uso.
UY34372A (es) Moléculas de ácido nucleico que se dirigen a rpa70 y confieren resistencia a plagas de coleópteros.
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
EP2900693A4 (en) ADCC-mediating antibodies, combinations and uses thereof
UY35795A (es) Anticuerpos que neutralizan la actividad de dabigatran,etexilato de dabigatran y o-acilglucurónidos de dabigatran
CL2012001927A1 (es) Anticuerpo capaz de neutralizar la actividad de un anticoagulante de dabigatran; método de fabricación de anticuerpo; kit que comprende al anticuerpo.
CY1125162T1 (el) Συριγγα
TH1201003589B (th) แอนติโดทของสารต้านการแข็งตัวของเลือด
NI201200143S (es) Motocicleta
TR201106798U (tr) Gizli çekmece rayı için kenetleme mekanizması.
TH1401000566B (th) แผ่นเส้นใยและวิธีการสำหรับการผลิตสิ่งที่คล้ายคลึงกัน